Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7393 - 7400 of 12007 results

IP Cases to Watch in 2017
January 12, 2017| Blog| Viewpoint

Grassley Continues To Press CMS on Medicaid Drug Rebate Classifications: What Will Be the Fallout?
January 12, 2017| Blog| Viewpoint

10 Years Out, Report Says Recession's Impact on Firms is Clear
January 12, 2017| News

Pizza! Pizza!: Little Caesar’s Repeated Term Slogans Are Not a “Family of Marks”
January 12, 2017| Blog| Viewpoint

FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress
January 12, 2017| Blog| Viewpoint

The Future of the ACA Week 5: The Rep. Tom Price Plan(s)
January 11, 2017| Blog| Viewpoint

Beyond the Eleventh Hour: FDA Prepares to Finalize Intended Use Amendments Despite Midnight Rule Relief Act
January 11, 2017| Blog| Viewpoint

U.S. Supreme Court to Hear Arguments on January 18, 2017 in "The Slants" Case.
January 11, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
